December 2021 FDA Recall Veklury by Gilead Sciences, Inc.
D-0299-2022 - Presence of Particulate Matter

This Class I drug recall was voluntarily initiated by Gilead Sciences, Inc. on December 3, 2021 for the product Veklury. The FDA reported the reason for recall as presence of particulate matter. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0299-2022

Reason for Recall
Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.
Initiated
12-03-2021
Reported
01-05-2022
Quantity
53,473 vials

Recall Profile & Regulatory Data

Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
Gilead Sciences, Inc.
Nationwide in the USA
Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2

Batch or Lot Expiration Information

Lot# Lots: 2141001-1A, 2141002-1A, Exp. 01/2024

Affected Packages Involved in this Recall